• NSC 87877: Applied Shp2 Inhibitor Workflows

  2026-09-02

  NSC 87877 is a research-ready Shp2 inhibitor for separating phosphatase activity from upstream receptor-complex assembly in signaling, cancer, and neuroinflammation models. This guide translates SHP2/NLRP3 findings from ischemic-stroke research into practical assay design, dosing, controls, and troubleshooting strategies.

• ML365 and NLRP3 in Postoperative Cognitive Impairment

  2026-09-01

  A 2024 Brain Research study reports that ML365 pretreatment reduced postoperative cognitive impairment in aged mice after exploratory laparotomy, alongside lower hippocampal NLRP3 inflammasome markers, improved tissue morphology, and reduced plasma oxidative stress. The work links two-pore potassium channel pharmacology with hippocampal neuroinflammation, while leaving direct TASK1 target engagement and translational relevance to be established.

• LDH Cytotoxicity Assay Kit: Cell Death Readout

  2026-09-01

  The LDH Cytotoxicity Assay Kit (K2228) supports cell cytotoxicity measurement through a 490 nm colorimetric readout of LDH released into culture medium. It provides a non-radioactive way to compare membrane damage across cancer research, nanomaterial, and disease-model experiments.

• 5-Azacytidine Workflow for DNA Demethylation

  2026-08-31

  Build reproducible 5-Azacytidine experiments by linking DNMT depletion to methylation, transcription, and phenotype-level readouts. This practical guide covers cancer-cell assays, MSC applications inspired by a recent osteoporosis study, formulation choices, and troubleshooting controls.

• Carvedilol Phosphate for Hepatic IRI Research

  2026-08-31

  Carvedilol Phosphate provides a practical adrenergic perturbation tool for connecting beta-receptor signaling with hepatocyte–macrophage behavior in ischemia–reperfusion assays. This guide translates the Arrb2–6-ketoLCA finding into formulation, workflow, controls, and troubleshooting decisions without overstating evidence.

• Quinolone–Coumarin Hybrids Against Toxoplasma gondii

  2026-08-30

  The 2024 Acta Parasitologica study evaluated 12 quinolone–coumarin hybrids derived from fluoroquinolones and novobiocin against Toxoplasma gondii in vitro. QC1, QC3, QC6, and novobiocin combined reduced host-cell toxicity with significant decreases in parasite infection, proliferation, and plaque formation, identifying a useful starting point for antiparasitic lead development.

• HyperFluor 488 Goat Anti-Rabbit IgG: Practical Guide

  2026-08-29

  HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody provides fluorescent detection of rabbit IgG primary antibodies in immunofluorescence, microscopy, flow cytometry, and related assays. It is intended for validated rabbit-primary workflows and should not be assumed suitable for non-rabbit primaries, direct antigen detection, or live-cell applications without compatibility testing.

• ETV5, EZH2, and Hepatocellular Carcinoma

  2026-08-28

  This study integrates pan-cancer transcriptomic and clinical analyses with hepatocellular carcinoma experiments to identify ETV5 as a prognostic, epigenetically linked driver of tumor progression. Its findings connect ETV5 regulation of EZH2 with increased proliferation and reduced sensitivity to the EZH2 inhibitor GSK126, providing a rationale for mechanistic studies of epigenetic drug response.

• BET Inhibition in HPV-16-Associated HNSCC

  2026-08-28

  This preprint examines how BET proteins regulate viral and cellular transcription in HPV-16-associated head and neck squamous cell carcinoma. Its main contribution is to show that BET inhibition produces heterogeneous viral responses while converging on selected host programs, including c-Myc and E2F suppression, CDKN1A induction, G1 arrest, and apoptosis.

• PX-478 2HCl: Practical HIF-1α Assay Guide

  2026-08-27

  A scenario-based guide to using PX-478 2HCl (SKU B6004) in viability, proliferation, cytotoxicity, and hypoxia studies. It connects product-defined handling parameters with controls, interpretation, radiosensitization experiments, and limitations when extending HIF-1α research into inflammatory models.

• NSC 87877: Applied Shp2 Inhibitor Workflows

  2026-08-27

  NSC 87877 enables controlled interrogation of Shp2/Shp1 phosphatase activity in EGF signaling, microglial neuroinflammation, leukemia models, and inflammatory pain research. This guide translates the Nespas/miR-383-3p/SHP2 stroke findings into practical assay designs while emphasizing target validation, timing, and interpretation limits.

• FITC Goat Anti-Rabbit IgG (H+L) Antibody Guide

  2026-08-26

  The FITC Goat Anti-Rabbit IgG (H+L) Antibody is a fluorescein-conjugated secondary antibody for detecting rabbit primary antibodies in immunofluorescence, fluorescence microscopy, and flow cytometry. Its affinity-purified polyclonal design supports signal amplification, while defined storage and handling conditions help preserve fluorescence and assay consistency.

• Matrine, YTHDF1, and Thymoma Stemness

  2026-08-26

  A 2026 study identifies a potential connection between Matrine treatment, reduced cancer stem cell-like behavior, and apoptosis in EL-4-B5 thymoma cells. The data implicate YTHDF1 and Wnt/β-catenin signaling, while the absence of direct m6A measurements, animal studies, and clinical validation makes the mechanism a testable hypothesis rather than an established therapeutic pathway.

• HyperPFU™ high-fidelity DNA polymerase Guide

  2026-08-25

  HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, and otherwise difficult DNA templates where processivity and proofreading are important. It produces blunt-ended products, so it should not be selected for workflows that require 3′-A overhangs or sticky-end generation.

• Apigenin: From HDAC Biology to Translational Strategy

  2026-08-25

  Apigenin is more than a plant-derived flavonoid: it is a research tool for connecting HDAC-linked apoptosis, oxidative stress, DNA damage, and inflammatory signaling across oncology and neurodegeneration models. This thought-leadership article outlines how to translate its preclinical evidence into better experimental design without overstating clinical maturity.

553 records 6/37 page Previous Next First page 上5页 678910 下5页 Last page